Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss

Retatrutide, Eli Lilly's "triple G" injection, is still in clinical development. Kateryna Borodina/Getty Images Eli Lilly is developing a more potent weight-loss drug called retatrutide. In the first head-to-head trial versus Ozempic, retatrutide takers lost roughly twice as much weight. Retatrutide is not FDA-approved yet, but some peptide sellers are skirting the law. Gym bros call it "reta." Eli Lilly is calling it the winner. On Wednesday, the pharmaceutical giant announced the results of the first clinical trial pitting Ozempic against its newest, most powerful, and yet-to-be-approved next-generation injectable medication for obesity and diabetes: retatrutide . Retatrutide won — and it wasn't even close. Type 2 diabetes patients on the highest dose of Ozempic (2 mg) lost an average of 21 pounds over a period of about a year and a half on the drug.